Amphastar Pharmaceuticals (AMPH) Gross Margin (2013 - 2026)
Amphastar Pharmaceuticals (AMPH) posted quarterly Gross Margin of 41.08% for Q1 2026, down 891.0% year-over-year from 5.19% in Q1 2025, and down 12.19% quarter-over-quarter from 46.79% in Q4 2025.
Amphastar Pharmaceuticals (AMPH) Gross Margin (2013 - 2026) Analysis & Trends
Amphastar Pharmaceuticals' Gross Margin history runs 14 years deep, the most recent figure standing at 41.08% for Q1 2026.
- In Q1 2026, Gross Margin fell 891.0% year-over-year to 41.08%; the TTM figure through Mar 2026 stood at 47.34% (down 316.0% YoY), while the FY2025 annual figure was 49.46%, down 162.0% from the prior year.
- Gross Margin for Q1 2026 stood at 41.08%, down from 46.79% in the prior quarter.
- The five-year high for Gross Margin was 60.04% in Q3 2023, with the low at 41.08% in Q1 2026.
- The 5-year median for Gross Margin is 51.31% (2022), against an average of 50.53%.
- The sharpest annual moves came in 2023 and 2026: Gross Margin soared 1133 bps in 2023, then sank 891 bps in 2026.
- Amphastar Pharmaceuticals' Gross Margin stood at 52.71% in 2022, then climbed by 2 bps to 53.98% in 2023, then declined by 14 bps to 46.45% in 2024, then advanced by 1 bps to 46.79% in 2025, then declined by 12 bps to 41.08% in 2026.
- Business Quant data shows AMPH's Gross Margin at 41.08% in Q1 2026, 46.79% in Q4 2025, and 51.42% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.07 Bn | 39.42 Bn | 2.15 Bn | 51.98% |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn | 42.63% |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 66.66% |
| 5 | United Therapeutics | 22.19 Bn | 19.53 Bn | 683.80 Mn | 87.30% |
| 6 | Viatris | 18.68 Bn | 17.79 Bn | 1.46 Bn | 38.77% |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | 97.58% |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 58.33% |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - | - |
| 10 | Amphastar Pharmaceuticals | 933.76 Mn | 643.64 Mn | 93.47 Mn | 50.83% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 50.83% |
| Mar 31, 2026 | 41.08% |
| Dec 31, 2025 | 46.79% |
| Sep 30, 2025 | 51.42% |
| Jun 30, 2025 | 49.59% |
| Mar 31, 2025 | 49.99% |
| Dec 31, 2024 | 46.45% |
| Sep 30, 2024 | 53.31% |
| Jun 30, 2024 | 52.18% |
| Mar 31, 2024 | 52.43% |
| Dec 31, 2023 | 53.98% |
| Sep 30, 2023 | 60.04% |
| Jun 30, 2023 | 49.92% |
| Mar 31, 2023 | 52.73% |
| Dec 31, 2022 | 52.71% |
| Sep 30, 2022 | 48.71% |
| Jun 30, 2022 | 51.31% |
| Mar 31, 2022 | 46.38% |
| Dec 31, 2021 | 46.52% |
| Sep 30, 2021 | 45.62% |